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Objective. The aim of this study is to develop a prognostic model capable of predicting the probability of signiﬁcant upgrading
among Japanese patients. Methods. The study cohort comprised 508 men treated with RP, with available prostate-speciﬁc antigen
levels, biopsy, and RP Gleason sum values. Clinical and pathological data from 258 patients were obtained from another Japanese
institution for validation. Results. Signiﬁcant Gleason sum upgrading was recorded in 92 patients (18.1%) at RP. The accuracy of
the nomogram predicting the probability of signiﬁcant Gleason sum upgrading between biopsy and RP specimens was 88.9%.
Overall AUC was 0.872 when applied to the validation data set. Nomogram predictions of signiﬁcant upgrading were within 7.5%
of an ideal nomogram. Conclusions. Nearly one-ﬁfth of Japanese patients with prostate cancer will be signiﬁcantly upgraded. Our
nomogram seems to provide considerably accurate predictions regardless of minor variations in pathological assessment when
applied to Japanese patient populations.
1.Introduction
Pretreatment prostate-speciﬁc antigen (PSA) level, Gleason
score, and pathological stage are generally recognized as
signiﬁcant predictors of biochemical recurrence in patients
with clinically localized prostate cancer treated by radical
prostatectomy (RP) [1]. A ﬁnding of high-grade disease
in RP specimens is an adverse prognostic factor, and such
tumors are signiﬁcantly more likely to progress than organ-
conﬁned cancers. In addition, this ﬁnding is associated
with a greater risk of positive surgical margins, further
decreasing the likelihood of long-term cancer control.
Determining whether a patient has high-grade disease
is thus important for treatment selection and prognosis
[2].
Chun et al. developed and validated a model predicting
Gleason sum upgrading from biopsy to ﬁnal pathology
using clinical variables (PSA level, clinical stage, and biopsy
Gleasonsum)[3].Thatmodelreliesonthreereadilyavailable
clinical variables, all of which are signiﬁcant uni- and
multivariate predictors of biopsy Gleason sum upgrading.
Based on the importance of the concept of Gleason sum
upgrading in decision making for prostate cancer, we
previously performed a formal external validation using a
fully independent data set in a contemporary cohort of
two Japanese institutions [4]. Unfortunately, our results
did not suggest that accurate predictions may be expected
when using this nomogram across diﬀerent racial patient
populations. Development of a nomogram predicting the
probability of biopsy Gleason sum upgrading in a large2 Prostate Cancer
multi-institutional cohort among Japanese patients thus
appears essential.
2.MaterialandMethods
Clinical and pathological data were prospectively gathered
from 837 consecutive patients at two centers (Department
of Urology in the Graduate School of Medicine at Chiba
University, Chiba (n = 327) and Division of Urology at
Chiba Cancer Center, Chiba (n = 510)). Of these, 71 patients
were excluded because of missing data.
Analyses targeted 766 evaluable patients assessed with
≥10 biopsy cores. All men had biopsy-conﬁrmed, clinically
localized prostate cancer, and all underwent RP between
January 2003 and December 2009. Patients treated with
neoadjuvant hormonal therapy were excluded, as the nomo-
gram is not applicable in these men.
Clinical stage was assigned by the attending urologist
according to the 2002 TNM system. Under transrectal
ultrasound (TRUS) guidance, 10–16 needle cores were
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digital rectal examination (DRE) and TRUS. Biopsy Gleason
sum was assigned by pathologists from each center. All RP
specimenswereprocessedaccordingto theStanfordprotocol
and graded according to the Gleason system [5].
Signiﬁcant upgrading was deﬁned as a biopsy Gleason
sum changing from ≤6t o≥7o rf r o m7t o≥8, according
to previous reports by King [6] and King and Long [7].
For both patient cohorts, the same predictors, that is,
PSA level, primary and secondary biopsy Gleason score,
and clinical stage, were used in uni- and multivariate
logistic regression models addressing the rate of signiﬁcant
Gleason sum upgrading between biopsy and RP pathology.
Coeﬃcients of multivariate logistic regression models were
then used to develop a nomogram predicting the proba-
bility of signiﬁcant Gleason sum upgrading, using the data
from one Japanese institution: the Division of Urology at
Chiba Cancer Center, Chiba (n = 508). The variables
were selected for the ﬁnal multivariate model by forward
stepwise selection. In addition, we utilized the bootstrap-
ping method to correct for overﬁt and the bias-corrected
coeﬃcients obtained from multivariate analysis to construct
the ﬁnal nomogram. Accuracy of the nomogram was
quantiﬁed using the receiver operating characteristics (ROC)
curve.
Validation data representing men treated with RP were
obtained from another Japanese institution: the Depart-
ment of Urology in the Graduate School of Medicine at
Chiba University, Chiba (n = 258). To determine the
nomogram-predicted probability of signiﬁcant Gleason sum
upgrading, we applied the nomogram (Figure 1)t oa l l
258 observations. Accuracy of the nomogram was then
quantiﬁed using the area under the curve (AUC) for external
validation. The extent of over- or underestimation relative
to the observed rate of signiﬁcant upgrading was explored
graphically using nonparametric Loess smoothing plots.
All tests were two sided with a signiﬁcance level set at
P<. 05.
3. Results
Table 1 lists the clinical and pathological characteristics of
patients included in this study, and data were stratiﬁed for
participating institutions. Pretreatment PSA levels were 2.5–
79.7ng/mL. Clinical stages T1c and T2 were recorded in 685
patients (89.4%). Among all men, 578 (75.5%) showed a
biopsy Gleason sum of 6 or 7.
In the Chiba Cancer Center dataset (508 men), concor-
dance between biopsy and RP Gleason sum was recorded in
258 (50.8%). Upgrading was recorded in 104 men (20.5%),
whereas 146 (28.7%) were downgraded. These data also
indicate that 69 patients (13.6%) were upgraded from biopsy
Gleason sum ≤6 to pathologic Gleason sum ≥7 .T h er a t eo f
upgrading from biopsy Gleason sum 7 to pathologic Gleason
sum ≥8 was 4.5% (n = 23). The overall rate of signiﬁcant
upgrading from biopsy to pathologic Gleason sum was
18.1% (92 patients). Conversely, Gleason sum decreased
from ≥8t o≤7 in 82men (16.1%) and from 7 to ≤6i n
36 (7.1%). Stratiﬁed according to institutions, agreement
between Gleason biopsy and ﬁnal pathology was more
frequent in the Chiba University data set (146men, 56.6%)
than in that from Chiba Cancer Center (50.8%). Signiﬁcant
upgrading was more frequent for Chiba University (64 men,
24.8%) than for Chiba Cancer Center (92, 18.1%). We
also investigated temporal changes in the rate of signiﬁcant
Gleason sum upgrading for two institutions. Although no
signiﬁcant correlation was found, a trend toward a decrease
in the rate of signiﬁcant upgrading since 2006 was seen.
Table 2 shows uni- and multivariate logistic regression
models for PSA, clinical stage, and primary and secondary
biopsy Gleason scores with corresponding uni- and multi-
variate predictive accuracy estimates. Clinical stage was not
associated with signiﬁcant upgrading in univariate analysis
(P = .131) and was excluded for multivariate analyses. In
univariate analyses, primary and secondary biopsy Gleason
scores were highly signiﬁcant predictors of signiﬁcant Glea-
son sum upgrading (P<. 001 and P = .002, resp.). Of all
predictors, secondary biopsy Gleason score (AUC = 0.784)
represented the most informative predictor, followed by
primary biopsy Gleason score (AUC = 0.712) and PSA (AUC
= 0.569). In multivariate analyses, all variables except for
clinical stage were highly signiﬁcant (P ≤ .001). Multivariate
200 bootstrap-corrected predictive accuracy was 88.9% and
exceeded the most informative univariate predictor, namely
secondary biopsy Gleason score (78.4%). Figure 1 shows the
regression coeﬃcient-based nomogram. High PSA values as
well as low primary and/or secondary biopsy Gleason scores
areriskfactorsforsigniﬁcantGleasonsumupgrading atﬁnal
pathology.
Figure 2 illustrates how predictions of the nomogram
are compared with actual probabilities for the validation
data (258 men). The x-axis represents nomogram pre-
dictions, and the y-axis represents the observed rate of
signiﬁcant Gleason upgrading for patients in the validation
cohort. Accuracy of the nomogram was 87.2% (conﬁdence
interval, 82.7–91.7%). The dashed 45
◦ line represents the
performance of an ideal nomogram, where predicted out-
come would correspond perfectly with actual outcome.Prostate Cancer 3
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Figure 1: Nomogram based on 508 patients treated at Chiba Cancer Center, for predicting signiﬁcant Gleason sum upgrading between
biopsyandradicalprostatectomy.PSA:prostate-speciﬁcantigen(ng/mL);Gl1:primarybiopsyGleasonscore;Gl2:secondarybiopsyGleason
score. To obtain the nomogram-predicted probability of signiﬁcant biopsy upgrading, locate the patient values at each axis, draw a vertical
line to the “Points” axis to determine how many points are attributed to each variable value; total the points for all variables, and locate
the sum on the “Total Points” line to assess the individual probability of signiﬁcant biopsy Gleason sum upgrading on the Probability of
Signiﬁcant Upgrading line.
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Figure 2: Calibration plot for external validation cohort. The x-
axis shows the prediction calculated using the nomogram, and the
y-axisgivesobservedratesofsigniﬁcantGleasonsumupgradingfor
patients in the validation cohort. Dashed line indicates reference
line, where an ideal nomogram would lie. Solid line indicates
performance of the nomogram applied to the validation cohort.
The solid line is close to the dashed line of the ideal nomogram and
is always within the 7.5% margin of error.
The performance of our nomogram is plotted as the solid
line. The dotted lines represent a 7.5% margin of error,
and the nomogram calibration plot demonstrated virtually
ideal predictions. The rate of predicted signiﬁcant Gleason
upgrading closely paralleled the observed rate of Gleason
upgrading, nearly corresponding to the 45
◦ line and always
within the 7.5% margin of error. The correspondence seen
between actual and ideal nomogram predictions suggests
good calibration of the nomogram in the validation cohort.
4. Discussion
Biopsy upgrading has important clinical implications in
terms of watchful waiting, surgery, and radiotherapy (RT)
candidates [8–10]. Most reported biopsy Gleason sums are
either 6 or 7, and these Gleason sums are at greatest
risk of being upgraded. However, tools have previously
been unavailable for reliably and accurately predicting this
phenomenon. Previous reports have indicated that with
more extended biopsy schemes, the risk of upgrading
decreases [8, 11] due to higher sampling density and more
accurate evaluation of the pathological biopsy. Extended
biopsy schemes (≥10 cores) might aﬀect the rate of and
ability to predict biopsy Gleason sum upgrading [12]. As
a result, ≥14 needle cores are currently obtained in our
institutions [13].
King [6] and King and Long [7] deﬁned signiﬁcant
Gleason sum upgrading as a Gleason sum increase either
from ≤6t o≥7o rf r o m7t o≥8 between biopsy and4 Prostate Cancer
Table 1: Descriptive characteristics of subgroups according to
institutions.
Variable Chiba Cancer Center Chiba University
n 508 258
Age (years)
Mean 66.902 65.054
SD 4.975 5.253
Median 67 65
Min 52 49
Max 78 76
PSA (ng/mL)
Mean 13.977 11.616
SD 12.194 9.732
Median 9.755 8.420
Min 2.588 2.450
Max 79.710 72.000
Clinical stage
(%)
T1c 169 (33.3) 180 (69.8)
T2a 172 (33.9) 32 (12.4)
T2b 89 (17.5) 15 (5.8)
T2c 12 (2.4) 16 (6.2)
T3 66 (13.0) 15 (5.8)
Biopsy Gleason
primary (%)
≤3 318 (62.6) 172 (66.7)
4 167 (32.9) 80 (31.0)
5 23 (4.5) 6(2.3)
Biopsy Gleason
secondary (%)
≤3 197 (38.8) 128 (49.6)
4 227 (44.7) 112 (43.4)
5 84 (16.5) 18 (7.0)
Biopsy Gleason
sum (%)
≤6 123 (24.2) 91 (35.3)
7 248 (48.8) 116 (45.0)
8 58 (11.4) 31 (12.0)
9 74 (14.6) 18 (7.0)
10 5 (1.0) 2 (0.8)
Pathological
Gleason
primary (%)
≤3 327 (64.4) 151 (58.5)
4 155 (30.5) 104 (40.3)
5 26 (5.1) 3 (1.2)
Pathological
Gleason
secondary (%)
≤3 209 (41.1) 114 (44.2)
4 241 (47.4) 119 (46.1)
5 58 (11.4) 25 (9.7)
Pathological
Gleason sum
(%)
≤6 93 (18.3) 44 (17.1)
7 332 (65.4) 176 (68.2)
8 21 (4.1) 11 (4.3)
9 60 (11.8) 27 (10.5)
10 2 (0.4) 0 (0.0)
Signiﬁcant
upgrading
Gleason sum (%)
92 (18.1) 64 (24.8)
RP specimens. They distinguished between any upgrading
and signiﬁcant upgrading and suggested that signiﬁcant
upgrading represents a clinically meaningful entity. Predict-
ing the rate of signiﬁcant upgrading would be much more
clinically meaningful, since these three categories represent
pathologically and clinically diﬀerent diseases. A preparative
Table 2: Uni- and multivariate logistic regression models predict-
ing signiﬁcant Gleason sum upgrading.
Predictors
Univariate
predictive
Univariate model Multivariate model
accuracy OR P OR P
Preoperative
PSA 0.569 1.020 .025 1.047 <.001
Clinical stage NA
1c 1.000
2a 0.978 .934 NA NA
2b 0.715 .334 NA NA
2c 0.000 .983 NA NA
3 0.528 .131 NA NA
Biopsy
Gleason
primary
0.712
2 1.000
3 0.250 <.001 1.210 .677
4 0.041 <.001 0.064 <.001
5 0.000 .983 0.000 .992
Biopsy
Gleason
secondary
0.784
2 1.000
3 1.491 .435 3.050 .041
4 0.189 .002 0.156 .001
5 0.000 .98 0.000 .986
Predictive
accuracy 0.889
OR: odds ratio; PSA: prostate-speciﬁc antigen; NA: not assessed.
nomogram predicting the probability of signiﬁcant Gleason
sum upgrading was developed among Western populations
[14]. Given the utility of the concept, creation of a new
prediction tool based on a modern, Japanese-only cohort
and aimed at predicting signiﬁcant upgrading represents a
worthwhile goal.
These ﬁndings are important as a ﬁrst substantial
depiction of the rate of signiﬁcant Gleason sum upgrading
in a Japanese contemporary cohort. Several applications
of these ﬁndings can be considered. For example, the
choice of interstitial brachytherapy might be reconsidered
in men who are at greater risk of biopsy Gleason sum
upgrading. Similarly, neoadjuvant hormonal therapy might
be considered if radiotherapy is contemplated. Finally,
among surgical candidates, the risk of signiﬁcant Gleason
sum upgrading might contribute to diﬀerent considerations
regarding the extent of neurovascular bundle resection and
the implications of positive surgical margins. However, the
decision of what level of risk is required for more aggressive
therapy remains controversial.
Chunetal.indicatedthattherateofupgradingdecreased
over time [3]. We also investigated temporal changes in the
rate of signiﬁcant Gleason sum upgrading and found noProstate Cancer 5
signiﬁcance. However, a trend toward a decreased rate of sig-
niﬁcant upgrading over time since 2006 was apparent. This
decrease may be due to the impact of the 2005 International
Society of Urological Pathology (ISUP) modiﬁed Gleason
grading system [15]. A shift towards a higher Gleason sum
on biopsy might also have occurred after the ISUP consensus
[16].
Prostate cancer is one of the most common cancers
among Western populations, and incidence is increasing
in Asia, although considerable diﬀerences in incidence and
biological aggressiveness remain between Western and Asian
populations [17]. Epidemiological and genetic diﬀerences
in prostate cancers exist between patients in Japan and the
United States, and p53 gene mutational analysis, which often
provides information about etiological factors, has revealed
clear diﬀerences in p53 gene mutational spectra between
Japanese and Western cases [18]. Diﬀerences in hormone
levels in various racial/ethnic groups have been suggested
to account for part of the diﬀerences in prostate cancer
risk. Racial/ethnic diﬀerences in the intraprostatic testos-
terone/dihydrotestosterone conversion ratio would provide
important support for the hypothesis that diﬀerences in the
enzymatic activity of 5a-reductase within the prostate gland
can explain most of the racial/ethnic diﬀerences in prostate
cancer risk [19–21].
We have previously performed a formal external valida-
tion of a preparative nomogram predicting the probability of
Gleason sum upgrading developed among Western popula-
tions, using a fully independent data set in a contemporary
cohort of two Japanese institutions [4]. The nomogram
providedreasonablyaccuratepredictionsregardlessofminor
variations in pathological assessment but could not nec-
essarily be considered accurate when applied to Japanese
patient populations. Our previous results suggested that
development of a nomogram predicting the probability of
biopsy Gleason sum upgrading in a large multi-institutional
cohort among Japanese patients is essential.
We are the ﬁrst to develop multivariate models to
predict signiﬁcant Gleason sum upgrading between biopsy
and RP in Japanese populations. Our current model was
88.9% accurate in predicting the probability of signiﬁcant
Gleason sum upgrading. To date, no other models capable
of accurately predicting the rate of signiﬁcant upgrading
are available for Japanese patients. Consequently, this model
represents the only alternative to clinical ratings of the
probability of signiﬁcant Gleason sum upgrading. We have
therefore tested the performance of the nomogram in an
external validation dataset, and overall AUC was 0.87. Indi-
vidual treatment centers in this study diﬀered with respect
to patient selection, extracapsular extension measurement,
and follow up assessment. Furthermore, no centralized
review of pathology was performed. For the purposes of
nomogramvalidation, suchheterogeneity isdesirabletogain
insights into how the nomogram will perform across varied
settings [22]. The nomogram was consistently accurate
at both centers, with AUC ranging from 0.87 to 0.89.
Our nomogram thus seems to provide reasonably accurate
predictions regardless of minor variations in pathological
assessment.
Clear limitations exist to this study. We included 10–16
core biopsy data in the cohort, but the diﬀerence in rate of
upgradingwasnotsigniﬁcantbetweenthesebiopsyregimens
according to the current data [14]. However, biopsy schemes
that rely on taking even more cores might be associated
with a lower rate of biopsy Gleason sum upgrading [23–
25]. In addition to the small population size, the level of
experience of pathologists could also aﬀect the ﬁndings.
Finally, model accuracy could potentially be improved by
integrating additional predictor variables, for example, the
level of expertise of the pathologist, or existing biomarkers
[26]. If the ISUP modiﬁed Gleason grading system or
central pathology diagnosis system was introduced, this
nomogram should be more useful for daily clinical practice.
Despitetheselimitations,ourmodelrepresentsanimportant
contribution concerning the rate of signiﬁcant Gleason sum
upgrading between biopsy and ﬁnal pathology.
5. Conclusions
Signiﬁcant Gleason sum upgrading between biopsy and
ﬁnal pathology represents an important consideration in
treatment decision making, even in most contemporary
patients. Our nomogram was 88.9% accurate in predict-
ing the probability of signiﬁcant Gleason sum upgrading,
and seems to provide accurate predictions regardless of
minor variations in pathological assessment when applied to
Japanese patient populations.
Abbreviations and Acronyms
RP: Radical prostatectomy
AUC: Area under the receiver operating
characteristic curve
PSA: Prostate-speciﬁc antigen
TRUS: Transrectal ultrasound
DRE: Digital rectal examination
ROC: Receiver operating characteristics
RT: Radiotherapy
ISUP: International Society of Urological
Pathology.
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